Table 2.
Patient characteristics
| Total (%) | AL-negative | AL-positive | p value | |
|---|---|---|---|---|
| N | 233 (100%) | 176 (75.5%) | 57 (24.5%) | |
| Sex | 0.299 | |||
| Male | 194 (83.26%) | 144 (61.8%) | 50 (21.5%) | |
| Female | 39 (16.74%) | 32 (13.7%) | 7 (3%) | |
| Tumor type | ||||
| None | 2 (0.9%) | |||
| AEG I-III | 170 (72.9%) | |||
| SCC | 60 (25.8%) | |||
| NEC | 1 (0.4%) | |||
| Neoadjuvant treatmenta | 182 (78.11%) | 136 (74.7%) | 46 (25.3%) | 0.71 |
| Reconstruction | 0.638 | |||
| Gastric tube | 229 (98.3%) | |||
| Colon | 4 (1.7%) | |||
| Length of ICU stay [days] | 7 ± 20.1 | 7 ± 14.2 | 19 ± 27.4 | < 0.001 |
| Length of hospitalization [days] | 19 ± 24.6 | 17 ± 15.5 | 46 ± 30.7 | < 0.001 |
| 30-day mortality | 8 (3.4%) | 2 (0.9%) | 6 (2.5%) | 0.005 |
AL: anastomotic leakage; AEG: adenocarcinoma of esophagogastric junction; SCC: squamous cell carcinoma; NEC: neuroendocrine carcinoma; ICU: intensive care unit
aRadio- and/or chemotherapy